CNP-106 clinical trial in myasthenia gravis (MG)
The purpose of this Phase 1b/2a study is to evaluate the safety and tolerability of CNP-106, an investigational treatment for MG. Participants will receive either CNP-106 or a placebo through an intravenous (IV) infusion on Day 1, Day 8, and, for some, Day 90.
A participant will be involved in the study for approximately 222 days, which includes screening (up to 42 days), active study participation (approximately 8 days) and a follow-up period (approximately 172 days).
Key inclusion requirements:
- Aged 18-75 years old
- Positive test for acetylcholine receptor antibodies
- Myasthenia Gravis Foundation of America (MGFA) Class II-IV diagnosis
Key exclusion requirements:
- Myasthenia Gravis Foundation of America Clinical Classification Class I or Class V
- If you have received a COVID-19 vaccine within 14 days of screening or are planning to receive any vaccination during your time on the study
Learn more about this study.
Find a study location near you
How many participants are being enrolled?
Approximately 54 participants across 30 centers in the US and Canada.
Are placebos part of the clinical trial?
Yes, participants will receive an infusion of either CNP-106 therapy or placebo (salt water).
How long is participation in the clinical trial?
~222 days: including screening, active study participation, and follow-up period. After completion of the trial, participants will be provided information on participation in a long-term follow-up study for an additional 1 year.